Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2008, Article ID 827096, 9 pages
http://dx.doi.org/10.1155/2008/827096
Review Article

The Role of PPAR 𝛾 Receptors and Leukotriene B 4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer

1Department of Physiology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates
2Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611-3008, USA
3Department of Surgery, Technische Universitaet Muenchen, 81675 Munich, Germany

Received 12 June 2008; Accepted 22 October 2008

Academic Editor: Dipak Panigrahy

Copyright © 2008 Thomas E. Adrian et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Jafari and J. L. Abbruzzese, “Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal intergroup pancreatic cancer task force,” Surgical Oncology Clinics of North America, vol. 13, no. 4, pp. 751–760, 2004. View at Publisher · View at Google Scholar · View at PubMed
  2. N. Alexakis, C. Halloran, M. Raraty, P. Ghaneh, R. Sutton, and J. P. Neoptolemos, “Current standards of surgery for pancreatic cancer,” British Journal of Surgery, vol. 91, no. 11, pp. 1410–1427, 2004. View at Publisher · View at Google Scholar · View at PubMed
  3. D. Goldstein, S. Carroll, M. Apte, and G. Keogh, “Modern management of pancreatic carcinoma,” Internal Medicine Journal, vol. 34, no. 8, pp. 475–481, 2004. View at Publisher · View at Google Scholar · View at PubMed
  4. M. P. Fay, L. S. Freedman, C. K. Clifford, and D. N. Midthune, “Effect of different types and amounts of fat on the development of mammary tumors in rodents: a review,” Cancer Research, vol. 57, no. 18, pp. 3979–3988, 1997. View at Google Scholar
  5. P. Clerc, N. Bensaadi, P. Pradel, A. Estival, F. Clemente, and N. Vaysse, “Lipid-dependent proliferation of pancreatic cancer cell lines,” Cancer Research, vol. 51, no. 14, pp. 3633–3638, 1991. View at Google Scholar
  6. T. L. Dao and R. Hilf, “Dietary fat and breast cancer: a search for mechanisms,” Advances in Experimental Medicine and Biology, vol. 322, pp. 223–237, 1992. View at Google Scholar
  7. R. Karmali, “n-3 fatty acids: biochemical actions in cancer,” Journal of Nutritional Science and Vitaminology, pp. 148–152, 1992. View at Google Scholar
  8. D. P. Rose and J. M. Connolly, “Dietary fat and breast cancer metastasis by human tumor xenografts,” Breast Cancer Research and Treatment, vol. 46, no. 2-3, pp. 225–237, 1997. View at Publisher · View at Google Scholar
  9. D. P. Rose, “Effects of dietary fatty acids on breast and prostate cancers: evidence from in vitro experiments and animal studies,” American Journal of Clinical Nutrition, vol. 66, pp. 1513S–1522S, 1997. View at Google Scholar
  10. S. M. Fischer, R. A. Hagerman, E. Li-Stiles et al., “Arachidonate has protumor-promoting action that is inhibited by linoleate in mouse skin carcinogenesis,” Journal of Nutrition, vol. 126, pp. 1099S–1104S, 1996. View at Google Scholar
  11. V. A. Ziboh, “Arachidonic acid metabolism in the skin,” in Arachidonic Acid Metabolism and Tumor Promotion, S. M. Fischer and T. J. Slaga, Eds., pp. 5–20, Martinus Nijhoff, Boston, Mass, USA, 1985. View at Google Scholar
  12. M. S. Simonson, J. A. Wolfe, and M. J. Dunn, “Regulation of prostaglandin synthesis by differential expression of the gene encoding prostaglandin endoperoxide synthase,” in Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Sammuelsson, P. Ramwell, and R. Paoletti, Eds., pp. 21–69, Raven Press, New York, NY, USA, 1990. View at Google Scholar
  13. W. L. Smith, D. L. DeWitt, S. A. Kraemer et al., “Structure function relationships in sheep, mouse, and human prostaglandin endoperoxide G/H synthases,” in Advances in Prostaglandin, Thromboxane and Leukotriene Research, B. Samuelsson, Ed., Raven Press, New York, NY, USA, 1990. View at Google Scholar
  14. M. J. Holtzman, V. Zhang, H. Hussain, W. T. Roswit, and J. D. Wilson, “Prostaglandin H synthase and lipoxygenase gene families in the epithelial cell barrier,” Annals of the New York Academy of Sciences, vol. 744, pp. 58–77, 1994. View at Publisher · View at Google Scholar
  15. C. D. Funk, “The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice,” Biochimica et Biophysica Acta, vol. 1304, no. 1, pp. 65–84, 1996. View at Publisher · View at Google Scholar
  16. C. D. Funk, “Prostaglandins and leukotrienes: advances in eicosanoid biology,” Science, vol. 294, no. 5548, pp. 1871–1875, 2001. View at Publisher · View at Google Scholar · View at PubMed
  17. M. Peters-Golden and T. G. Brock, “5-lipoxygenase and FLAP,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 2-3, pp. 99–109, 2003. View at Publisher · View at Google Scholar
  18. C. A. Sorkness, “The use of 5-lipoxygenase inhibitors and leukotriene receptor antagonists in the treatment of chronic asthma,” Pharmacotherapy, vol. 17, no. 1, part 2, pp. 50S–54S, 1997. View at Google Scholar
  19. J. M. Negro, J. C. Miralles, J. L. Ortiz, E. Funes, and A. García, “Biosynthesis inhibitors for leukotrienes in bronchial asthma,” Allergologia et Immunopathologia, vol. 25, no. 4, pp. 209–216, 1997. View at Google Scholar
  20. A. R. Leff, “Discovery of leukotrienes and development of antileukotriene agents,” Annals of Allergy, Asthma and Immunology, vol. 86, no. 6, supplement 1, pp. 4–8, 2001. View at Google Scholar
  21. S. W. Djuric, P. W. Collins, P. H. Jones et al., “7-[3-(4-Acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8-propyl-2H- 1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist,” Journal of Medicinal Chemistry, vol. 32, no. 6, pp. 1145–1147, 1989. View at Publisher · View at Google Scholar
  22. D. J. Fretland, D. L. Widomski, J. M. Zemaitis, S. W. Djurić, and R. L. Shone, “Effect of a leukotriene B4 receptor antagonist on leukotriene B4-induced neutrophil chemotaxis in cavine dermis,” Inflammation, vol. 13, no. 5, pp. 601–605, 1989. View at Publisher · View at Google Scholar
  23. B. S. Tsai, D. Villani-Price, R. H. Keith et al., “SC-41930: an inhibitor of leukotriene B4-stimulated human neutrophil functions,” Prostaglandins, vol. 38, no. 6, pp. 655–674, 1989. View at Publisher · View at Google Scholar
  24. K. Kishikawa, N. Tateishi, T. Maruyama, R. Seo, M. Toda, and T. Miyamoto, “ONO-4057, a novel orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions,” Prostaglandins, vol. 44, no. 4, pp. 261–275, 1992. View at Publisher · View at Google Scholar
  25. K. Kishikawa, S. Nakao, S. Matsumoto, K. Kondo, and N. Hamanaka, “Estimation of antagonistic activity of ONO-4057 against leukotriene B4 in humans,” Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 23, pp. 279–281, 1995. View at Google Scholar
  26. D. M. Gapinski, B. E. Mallett, L. L. Froelich, and W. T. Jackson, “Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain,” Journal of Medicinal Chemistry, vol. 33, no. 10, pp. 2807–2813, 1990. View at Publisher · View at Google Scholar
  27. W. T. Jackson, R. J. Boyd, L. L. Froelich, B. E. Mallett, and D. M. Gapinski, “Specific inhibition of leukotriene B4-induced neutrophil activation by LY223982,” Journal of Pharmacology and Experimental Therapeutics, vol. 263, no. 3, pp. 1009–1014, 1992. View at Google Scholar
  28. P. Marder, J. S. Sawyer, L. L. Froelich, L. L. Mann, and S. M. Spaethe, “Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]propoxy] phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist,” Biochemical Pharmacology, vol. 49, no. 11, pp. 1683–1690, 1995. View at Publisher · View at Google Scholar
  29. J. S. Sawyer, N. J. Bach, S. R. Baker et al., “Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist,” Journal of Medicinal Chemistry, vol. 38, no. 22, pp. 4411–4432, 1995. View at Publisher · View at Google Scholar
  30. J. S. Sawyer, “LY293111Na,” Drugs of the Future, vol. 21, pp. 610–614, 1996. View at Google Scholar
  31. L. M. Coussens and Z. Werb, “Inflammation and cancer,” Nature, vol. 420, no. 6917, pp. 860–867, 2002. View at Publisher · View at Google Scholar · View at PubMed
  32. M. Macarthur, G. L. Hold, and E. M. El-Omar, “Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy,” American Journal of Physiology, vol. 286, no. 4, pp. G515–G520, 2004. View at Google Scholar
  33. W. G. Nelson, A. M. De Marzo, T. L. DeWeese et al., “The role of inflammation in the pathogenesis of prostate cancer,” The Journal of Urology, vol. 172, no. 5, supplement 1, pp. S6–S12, 2004. View at Publisher · View at Google Scholar
  34. C. Bréchot, “Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms,” Gastroenterology, vol. 127, no. 5, supplement 1, pp. S56–S61, 2004. View at Publisher · View at Google Scholar
  35. A. Tannapfel, “Molecular findings in Barrett's epithelium,” Digestive Diseases, vol. 22, no. 2, pp. 126–133, 2004. View at Publisher · View at Google Scholar · View at PubMed
  36. H. Clevers, “At the crossroads of inflammation and cancer,” Cell, vol. 118, no. 6, pp. 671–674, 2004. View at Publisher · View at Google Scholar · View at PubMed
  37. C. Stoicov, R. Saffari, X. Cai, C. Hasyagar, and J. Houghton, “Molecular biology of gastric cancer: helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling,” Gene, vol. 341, no. 1-2, pp. 1–17, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. A. D. Feld, “Malpractice risks associated with colon cancer and inflammatory bowel disease,” American Journal of Gastroenterology, vol. 99, no. 9, pp. 1641–1644, 2004. View at Publisher · View at Google Scholar · View at PubMed
  39. S. Zha, V. Yegnasubramanian, W. G. Nelson, W. B. Isaacs, and A. M. De Marzo, “Cyclooxygenases in cancer: progress and perspective,” Cancer Letters, vol. 215, no. 1, pp. 1–20, 2004. View at Publisher · View at Google Scholar · View at PubMed
  40. C. J. van der Woude, J. H. Kleibeuker, P. L. M. Jansen, and H. Moshage, “Chronic inflammation, apoptosis and (pre-)malignant lesions in the gastro-intestinal tract,” Apoptosis, vol. 9, no. 2, pp. 123–130, 2004. View at Publisher · View at Google Scholar · View at PubMed
  41. B. Farrow and B. M. Evers, “Inflammation and the development of pancreatic cancer,” Surgical Oncology, vol. 10, no. 4, pp. 153–169, 2002. View at Publisher · View at Google Scholar
  42. O. C. Trifan and T. Hla, “Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis,” Journal of Cellular and Molecular Medicine, vol. 7, no. 3, pp. 207–222, 2003. View at Publisher · View at Google Scholar
  43. X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer,” Pancreatology, vol. 1, no. 4, pp. 291–299, 2001. View at Publisher · View at Google Scholar
  44. Y. Cao and S. M. Prescott, “Many actions of cyclooxygenase-2 in cellular dynamics and in cancer,” Journal of Cellular Physiology, vol. 190, no. 3, pp. 279–286, 2002. View at Publisher · View at Google Scholar · View at PubMed
  45. E. Fosslien, “Review: molecular pathology of cyclooxygenase-2 in cancer-induced angiogenesis,” Annals of Clinical and Laboratory Science, vol. 31, no. 4, pp. 325–348, 2001. View at Google Scholar
  46. S. Gately and W. W. Li, “Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy,” Seminars in Oncology, vol. 31, pp. 2–11, 2004. View at Publisher · View at Google Scholar
  47. C. Rüegg, O. Dormond, and A. Mariotti, “Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis,” Biochimica et Biophysica Acta, vol. 1654, no. 1, pp. 51–67, 2004. View at Publisher · View at Google Scholar · View at PubMed
  48. M. J. Thun, “Aspirin, NSAIDs, and digestive tract cancers,” Cancer and Metastasis Reviews, vol. 13, no. 3-4, pp. 269–277, 1994. View at Publisher · View at Google Scholar
  49. M. J. Thun, “NSAID use and decreased risk of gastrointestinal cancers,” Gastroenterology Clinics of North America, vol. 25, no. 2, pp. 333–348, 1996. View at Publisher · View at Google Scholar
  50. G. N. Levy, “Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer,” The FASEB Journal, vol. 11, no. 4, pp. 234–247, 1997. View at Google Scholar
  51. J. A. Baron and R. S. Sandler, “Nonsteroidal anti-inflammatory drugs and cancer prevention,” Annual Review of Medicine, vol. 51, pp. 511–523, 2000. View at Publisher · View at Google Scholar · View at PubMed
  52. T. J. Kennedy, C.-Y. Chan, X.-Z. Ding, and T. E. Adrian, “Lipoxygenase inhibitors for the treatment of pancreatic cancer,” Expert Review of Anticancer Therapy, vol. 3, no. 4, pp. 525–536, 2003. View at Publisher · View at Google Scholar · View at PubMed
  53. C. E. Myers and J. Ghosh, “Lipoxygenase inhibition in prostate cancer,” European Urology, vol. 35, no. 5-6, pp. 395–398, 1999. View at Publisher · View at Google Scholar
  54. W. G. Jiang, A. Douglas-Jones, and R. E. Mansel, “Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 69, no. 4, pp. 275–281, 2003. View at Publisher · View at Google Scholar
  55. M. Matsuyama, R. Yoshimura, M. Mitsuhashi et al., “Expression of lipoxygenase in human prostate cancer and growth reduction by its inhibitors,” International Journal of Oncology, vol. 24, no. 4, pp. 821–827, 2004. View at Google Scholar
  56. S. Gupta, M. Srivastava, N. Ahmad, K. Sakamoto, D. G. Bostwick, and H. Mukhtar, “Lipoxygenase-5 is overexpressed in prostate adenocarcinoma,” Cancer, vol. 91, no. 4, pp. 737–743, 2001. View at Publisher · View at Google Scholar
  57. J. Ghosh and C. E. Myers, “Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 22, pp. 13182–13187, 1998. View at Publisher · View at Google Scholar
  58. J. Ghosh and C. E. Myers, “Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells,” Advances in Experimental Medicine and Biology, vol. 469, pp. 577–582, 1999. View at Google Scholar
  59. K. M. Anderson, T. Seed, J. Meng, D. Ou, W. A. Alrefai, and J. E. Harris, “Five-lipoxygenase inhibitors reduce PANC-1 survival: the mode of cell death and synergism of MK886 with gamma linolenic acid,” Anticancer Research, vol. 18, no. 2, pp. 791–800, 1998. View at Google Scholar
  60. M. Romano, A. Catalano, M. Nutini et al., “5-lipoxygenase regulates malignant mesothelial cell survival: involvement of vascular endothelial growth factor,” The FASEB Journal, vol. 15, no. 13, pp. 2326–2336, 2001. View at Publisher · View at Google Scholar · View at PubMed
  61. X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “Multiple signal pathways are involved in the mitogenic effect of 5(S)-HETE in human pancreatic cancer,” Oncology, vol. 65, no. 4, pp. 285–294, 2003. View at Publisher · View at Google Scholar · View at PubMed
  62. W.-G. Tong, X.-Z. Ding, M. S. Talamonti, R. H. Bell, and T. E. Adrian, “LTB4 stimulates growth of human pancreatic cancer cells via MAPK and PI-3 kinase pathways,” Biochemical and Biophysical Research Communications, vol. 335, no. 3, pp. 949–956, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. X.-Z. Ding, W.-G. Tong, and T. E. Adrian, “12-lipoxygenase metabolite 12(S)-HETE stimulates human pancreatic cancer cell proliferation via protein tyrosine phosphorylation and ERK activation,” International Journal of Cancer, vol. 94, no. 5, pp. 630–636, 2001. View at Publisher · View at Google Scholar · View at PubMed
  64. R. Hennig, T. Kehl, S. Noor et al., “15-lipoxygenase-1 production is lost in pancreatic cancer and overexpression of the gene inhibits tumor cell growth,” Neoplasia, vol. 9, no. 11, pp. 917–926, 2007. View at Publisher · View at Google Scholar
  65. R. Hennig, X.-Z. Ding, W.-G. Tong et al., “5-lipoxygenase and leukotriene B4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue,” American Journal of Pathology, vol. 161, no. 2, pp. 421–428, 2002. View at Google Scholar
  66. R. Hennig, P. Grippo, X.-Z. Ding et al., “5-lipoxygenase, a marker for early pancreatic intraepithelial neoplastic lesions,” Cancer Research, vol. 65, no. 14, pp. 6011–6016, 2005. View at Publisher · View at Google Scholar · View at PubMed
  67. X.-Z. Ding, C. A. Kuszynski, T. H. El-Metwally, and T. E. Adrian, “Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells,” Biochemical and Biophysical Research Communications, vol. 266, no. 2, pp. 392–399, 1999. View at Publisher · View at Google Scholar · View at PubMed
  68. X.-Z. Ding, P. Iversen, M. W. Cluck, J. A. Knezetic, and T. E. Adrian, “Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells,” Biochemical and Biophysical Research Communications, vol. 261, no. 1, pp. 218–223, 1999. View at Publisher · View at Google Scholar · View at PubMed
  69. W. G. Tong, X. Z. Ding, R. C. Witt, and T. E. Adrian, “Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway,” Molecular Cancer Therapeutics, vol. 1, no. 11, pp. 929–935, 2002. View at Google Scholar
  70. R. Hennig, X. Z. Ding, W. G. Tong et al., “The leukotriene receptor: BLT2R is overexpressed in pancreatic intraepithelial neoplastic lesion (PanINS): a new target for therapy?,” Pancreas, vol. 29, no. 4, p. 336, 2004. View at Publisher · View at Google Scholar
  71. S. J. Roberts-Thomson, “Peroxisome proliferator-activated receptors in tumorigenesis: targets of tumour promotion and treatment,” Immunology and Cell Biology, vol. 78, no. 4, pp. 436–441, 2000. View at Publisher · View at Google Scholar
  72. L. Kopelovich, J. R. Fay, R. I. Glazer, and J. A. Crowell, “Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents,” Molecular Cancer Therapeutics, vol. 1, no. 5, pp. 357–363, 2002. View at Google Scholar
  73. H. P. Koeffler, “Peroxisome proliferator-activated receptor γ and cancers,” Clinical Cancer Research, vol. 9, no. 1, pp. 1–9, 2003. View at Google Scholar
  74. C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004. View at Publisher · View at Google Scholar · View at PubMed
  75. W. Motomura, T. Okumura, N. Takahashi, T. Obara, and Y. Kohgo, “Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27(Kip1) in human pancreatic carcinoma cells,” Cancer Research, vol. 60, no. 19, pp. 5558–5564, 2000. View at Google Scholar
  76. R. G. Mehta, E. Williamson, M. K. Patel, and H. P. Koeffler, “A ligand of peroxisome proliferator-activated receptor γ, retinoids, and prevention of preneoplastic mammary lesions,” Journal of the National Cancer Institute, vol. 92, no. 5, pp. 418–423, 2000. View at Publisher · View at Google Scholar
  77. T. Sasaki, Y. Fujimoto, A. Tsuchida, Y. Kawasaki, Y. Kuwada, and K. Chayama, “Activation of peroxisome proliferator-activated receptor gamma inhibits the growth of human pancreatic cancer,” Pathobiology, vol. 69, no. 5, pp. 258–265, 2001. View at Publisher · View at Google Scholar
  78. A. Itami, G. Watanabe, Y. Shimada et al., “Ligands for peroxisome proliferator-activated receptor γ inhibit growth of pancreatic cancers both in vitro and in vivo,” International Journal of Cancer, vol. 94, no. 3, pp. 370–376, 2001. View at Publisher · View at Google Scholar · View at PubMed
  79. G. Eibl, M. N. Wente, H. A. Reber, and O. J. Hines, “Peroxisome proliferator-activated receptor γ induces pancreatic cancer cell apoptosis,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 522–529, 2001. View at Publisher · View at Google Scholar · View at PubMed
  80. S. Kawa, T. Nikaido, H. Unno, N. Usuda, K. Nakayama, and K. Kiyosawa, “Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone,” Pancreas, vol. 24, no. 1, pp. 1–7, 2002. View at Publisher · View at Google Scholar
  81. K. Hashimoto, B. J. Farrow, and B. M. Evers, “Activation and role of MAP kinases in 15d-PGJ2-induced apoptosis in the human pancreatic cancer cell line MIA PaCa-2,” Pancreas, vol. 28, no. 2, pp. 153–159, 2004. View at Publisher · View at Google Scholar
  82. E. Ceni, T. Mello, M. Tarocchi et al., “Antidiabetic thiazolidinediones induce ductal differentiation but not apoptosis in pancreatic cancer cells,” World Journal of Gastroenterology, vol. 11, no. 8, pp. 1122–1130, 2005. View at Google Scholar
  83. W. Motomura, M. Nagamine, S. Tanno et al., “Inhibition of cell invasion and morphological change by troglitazone in human pancreatic cancer cells,” Journal of Gastroenterology, vol. 39, no. 5, pp. 461–468, 2004. View at Publisher · View at Google Scholar · View at PubMed
  84. A. Galli, E. Ceni, D. W. Crabb et al., “Antidiabetic thiazolidinediones inhibit invasiveness of pancreatic cancer cells via PPARγ independent mechanisms,” Gut, vol. 53, no. 11, pp. 1688–1697, 2004. View at Publisher · View at Google Scholar · View at PubMed
  85. G. Eibl, Y. Takata, L. G. Boros et al., “Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor,” Cancer Research, vol. 65, no. 3, pp. 982–990, 2005. View at Google Scholar
  86. W.-G. Tong, X.-Z. Ding, R. Hennig et al., “Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells,” Clinical Cancer Research, vol. 8, no. 10, pp. 3232–3242, 2002. View at Google Scholar
  87. W.-G. Tong, X.-Z. Ding, M. S. Talamonti, R. H. Bell, and T. E. Adrian, “Leukotriene B4 receptor antagonist LY293111 induces S-phase cell cycle arrest and apoptosis in human pancreatic cancer cells,” Anti-Cancer Drugs, vol. 18, no. 5, pp. 535–541, 2007. View at Publisher · View at Google Scholar · View at PubMed
  88. W.-G. Tong, X.-Z. Ding, and T. E. Adrian, “The mechanisms of lipoxygenase inhibitor-induced apoptosis in human breast cancer cells,” Biochemical and Biophysical Research Communications, vol. 296, no. 4, pp. 942–948, 2002. View at Publisher · View at Google Scholar
  89. R. Hennig, X.-Z. Ding, W.-G. Tong, R. C. Witt, B. D. Jovanovic, and T. E. Adrian, “Effect of LY293111 in combination with gemcitabine in colonic cancer,” Cancer Letters, vol. 210, no. 1, pp. 41–46, 2004. View at Publisher · View at Google Scholar · View at PubMed
  90. R. C. Falcone and D. Aharony, “Modulation of ligand binding to leukotriene B4 receptors on guinea pig lung membranes to sulfhydryl modifying reagents,” Journal of Pharmacology and Experimental Therapeutics, vol. 255, no. 2, pp. 565–571, 1990. View at Google Scholar
  91. R. Hennig, J. Ventura, R. Segersvard et al., “LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice,” Neoplasia, vol. 7, no. 4, pp. 417–425, 2005. View at Publisher · View at Google Scholar
  92. M. S. Marshall, B. Diaz, J. Brozinick et al., “LY293111 inhibits tumor cell growth cell growth in vitro through an apparent PPARgamma agonist activity,” in Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR '02), vol. 43, p. 957, San Francisco, Calif, USA, April 2002.
  93. M. S. Marshall, B. Diaz, J. Copp et al., “The LTB4 receptor antagonist, LY2931111 inhibits tumor cell growth in vitro independent of the LTB4 receptor,” in Proceedings 93rd Annual Meeting of American Association for Cancer Research (AACR '02), vol. 43, p. 963, San Francisco, Calif, USA, April 2002.
  94. D. R. Budman and A. Calabro, “Studies of synergistic and antagonistic combinations of conventional cytotoxic agents with the multiple eicosanoid pathway modulator LY 293111,” Anti-Cancer Drugs, vol. 15, no. 9, pp. 877–881, 2004. View at Publisher · View at Google Scholar
  95. G. K. Schwartz, D. R. Budman, S. Endres et al., “Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPARγ),” in Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO '02), vol. 21, Orlando, Fla, USA, May 2002, abstract 343.
  96. J. P. Stevenson, D. P. Petrylak, K. Feit et al., “Phase I and pharmacological trial of LY293111 in combination with gemcitabine,” in Proceedings of the 38th Annual Meeting of the American Society of Clinical Oncology (ASCO '02), vol. 21, Orlando, Fla, USA, May 2002, abstract 2140.
  97. T. Baetz, E. Eisenhauer, L. Siu et al., “A phase I study of oral LY293111 given daily in combination with irinotecan in patients with solid tumours,” Investigational New Drugs, vol. 25, no. 3, pp. 217–225, 2007. View at Publisher · View at Google Scholar · View at PubMed
  98. D. A. Richards, H. Oettle, W. L. Vervenne et al., “Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas,” Journal of Clinical Oncology, vol. 23, no. 16s, p. 4092, 2005. View at Google Scholar
  99. P. A. Janne, P.-A. Rodriguez, M. Gottfried et al., “Randomized phase II trial of cisplatin/gemcitabine with or without LY293111, a multiple eicosanoid pathway modulator, in patients with chemotherapy naïve advanced non-small cell lung carcinoma,” Journal of Clinical Oncology, vol. 24, no. 18s, p. 7024, 2006. View at Google Scholar